Pharmacotherapy for Alcohol Use Disorder

Pharmacotherapy for alcohol use disorder is the use of medications to help people reduce or stop drinking and to prevent relapse, used alongside psychosocial treatment. The medications with the strongest evidence are naltrexone and acamprosate, with disulfiram acting through an aversive mechanism.

Definition

Pharmacotherapy for alcohol use disorder is the use of medications such as naltrexone, acamprosate, and disulfiram, combined with psychosocial support, to reduce craving and drinking, support abstinence, or deter drinking through an aversive reaction.

Scope

This topic covers the principal medications studied for alcohol use disorder, their differing pharmacological rationales, and the meta-analytic evidence for their efficacy. It is a reference entry within addiction pharmacotherapy and does not give dosing or prescribing guidance.

Core questions

• Which medications have demonstrated efficacy for alcohol use disorder in meta-analysis?
• How do naltrexone, acamprosate, and disulfiram differ in mechanism?
• What drinking outcomes (abstinence, heavy-drinking days) do these medications affect?
• Why are these medications combined with psychosocial treatment?

Key concepts

• Alcohol use disorder
• Naltrexone (opioid antagonist)
• Acamprosate
• Disulfiram (aversive therapy)
• Craving reduction
• Relapse prevention
• Return to heavy drinking

Mechanisms

The approved medications work through distinct mechanisms. Naltrexone is an opioid antagonist that blunts the reinforcing, rewarding effects of alcohol mediated through the endogenous opioid system, reducing heavy drinking and craving. Acamprosate is thought to modulate glutamatergic and GABAergic neurotransmission disrupted by chronic alcohol exposure, helping to maintain abstinence after withdrawal. Disulfiram acts by a different logic: it inhibits aldehyde dehydrogenase, so that drinking produces an accumulation of acetaldehyde and an unpleasant reaction, deterring alcohol use through aversion rather than craving reduction. The meta-analysis by Jonas and colleagues and the Cochrane review of opioid antagonists by Rösner and colleagues summarize the supporting evidence.

Clinical relevance

Several medications meaningfully improve drinking outcomes in alcohol use disorder yet remain underused; understanding their mechanisms supports informed reading of the treatment literature. This entry is descriptive and educational and does not provide individualized treatment or dosing recommendations, which are governed by current clinical guidelines.

Epidemiology

Alcohol use disorder is among the most prevalent substance use disorders and a leading contributor to the global burden of disease. Despite effective medications, only a small minority of affected people receive pharmacotherapy.

Evidence & guidelines

Meta-analytic evidence supports naltrexone and acamprosate for reducing return to drinking and heavy drinking, and major guidelines recommend them as first-line options, with disulfiram as a supervised alternative in selected patients. DSM-5 defines alcohol use disorder; specific recommendations should be drawn from current guidelines rather than from this entry.

History

Disulfiram, introduced in the mid-twentieth century, was the first widely used medication for alcohol dependence, working by aversion. Naltrexone and acamprosate were approved in the 1990s on the basis of trials showing reduced relapse and heavy drinking, shifting the field toward craving- and reward-focused pharmacology and a chronic-disease framing of alcohol use disorder.

Debates

Comparative efficacy and choice among alcohol medications

Naltrexone and acamprosate both have meta-analytic support but appear to suit different goals and patient profiles, and head-to-head superiority remains uncertain; the place of disulfiram, which depends on adherence and supervision, is also debated.

Key figures

• Daniel Jonas
• Susanne Rösner
• Nora Volkow

Seminal works

• jonas-2014
• rosner-2010

Frequently asked questions

Which medications are considered first-line for alcohol use disorder?

Naltrexone and acamprosate have the strongest meta-analytic evidence and are generally recommended as first-line options, while disulfiram works by an aversive mechanism and is typically reserved for selected, supervised situations.

How does disulfiram differ from naltrexone?

Disulfiram deters drinking by causing an unpleasant reaction if alcohol is consumed, whereas naltrexone reduces the reward and craving associated with drinking; one works through aversion and the other through reward reduction.